Compare AU
Compare CURE vs. GRNV
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the VanEck MSCI Australian Sustainable Equity ETF (GRNV). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | GRNV | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 582 |
Median incremental investment | $619.50 | $671.05 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $1,417.68 |
Average age group | > 35 | 26 - 35 |
Key Summary
CURE | GRNV | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | GRNV.AX was created on 2016-04-27 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. GRNV.AX gives investors access to a diversified portfolio of sustainable Australian companies selected on the basis of in-depth analysis by world leading research agency MSCI ESG Research. GRNV.AX aims to provide investment returns, before fees and other costs, which track the performance of the Index. |
Top 3 holdings | Natera Inc (3.41 %) Incyte Corp (2.94 %) Gilead Sciences Inc (2.88 %) | Telstra Group Ltd (5.19 %) Transurban Group (5.09 %) Goodman Group (5.03 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Financials (28.44 %) Industrials (20.96 %) Communication Services (12.25 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | Australia (94.04 %) New Zealand (3.05 %) United States (2.91 %) |
Management fee | 0.45 % | 0.35 % |
Key Summary
CURE | GRNV | |
|---|---|---|
Issuer | Global X | VanEck |
Tracking index | S&P Biotechnology Select Industry | MSCI Australia IMI Select SRI Screened Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.35 % |
Price | $49.94 | $32.22 |
Size | $38.065 million | $178.163 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | 4.15 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 02/05/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | GRNV | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 582 |
Median incremental investment | $619.50 | $671.05 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $1,417.68 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
CURE | GRNV | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | GRNV |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |